PA
SWTX

Parallel Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Parallel Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,086
Closed -$98K – 3687
2025
Q2 		$98K Sell
2,086
-2,132
-51% -$94.8K ﹤0.01% 1364
2025
Q1 		$186K Sell
4,218
-2,846
-40% -$131K ﹤0.01% 991
2024
Q4 		$255K Sell
7,064
-391
-5% -$13.7K 0.01% 829
2024
Q3 		$239K Sell
7,455
-118
-2% -$4.41K 0.01% 851
2024
Q2 		$285K Sell
7,573
-34
-0.4% -$1.43K 0.01% 730
2024
Q1 		$374K Buy
7,607
+38
+0.5% +$1.76K 0.01% 623
2023
Q4 		$276K Sell
7,569
-11
-0.1% -$287 0.01% 675
2023
Q3 		$175K Buy
7,580
+442
+6% +$12.1K 0.01% 831
2023
Q2 		$187K Buy
7,138
+4
+0.1% +$105 0.01% 807
2023
Q1 		$184K Sell
7,134
-5
-0.1% -$146 0.01% 815
2022
Q4 		$186K Buy
7,139
+5,876
+465% +$145K 0.01% 730
2022
Q3 		$36K Buy
1,263
+169
+15% +$4.84K ﹤0.01% 1412
2022
Q2 		$27K Buy
1,094
+66
+6% +$2.41K ﹤0.01% 1534
2022
Q1 		$61K Buy
1,028
+265
+35% +$15.2K ﹤0.01% 1206
2021
Q4 		$47K Buy
+763
New +$50.5K ﹤0.01% 1354

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Parallel Advisors's SWTX Position: Q3 2025 in Review

Parallel Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 2,086 shares — an estimated $98K sold.

Parallel Advisors first reported a position in SWTX in Q4 2021 and held it in 15 quarters. The position peaked at $374K in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Parallel Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parallel Advisors sold 2,086 SpringWorks Therapeutics shares in Q3 2025, an estimated $98K.
  • Parallel Advisors first reported a position in SpringWorks Therapeutics in Q4 2021 and held it in 15 quarters.
  • Parallel Advisors's SpringWorks Therapeutics position peaked at $374K in Q1 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.